SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Payments of Financing Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Payments of Financing Costs of $74.15 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for the quarter ending 2025-12-31 was -$4.26K, a 172.98% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for the quarter ending 2025-09-30 was $0.00.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for the quarter ending 2025-06-30 was $28.41K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for the quarter ending 2025-03-31 was $50.00K, a 25.00% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for fiscal 2025 was $74.15K, a 31.02% decline from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for fiscal 2024 was $107.49K, a 68.84% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for fiscal 2023 was $345.00K, a 1886.98% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. payments of financing costs for fiscal 2022 was $17.36K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$4.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.26K derived: sum of 2 quarters · filed 2026-03-31 | $24.15K derived: sum of 3 quarters · filed 2026-09-24 | $74.15K 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $28.41K derived: sum of 2 quarters · filed 2026-09-24 | $78.41K 10-Q · filed 2025-11-13 | $84.25K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | $28.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $78.41K 10-Q · filed 2026-09-24 | $84.25K derived: sum of 3 quarters · filed 2026-09-24 | |
| 2025-03-31 | $50.00K 10-Q · filed 2026-05-15 | $55.84K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $5.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $107.49K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $101.65K 10-Q · filed 2025-11-13 | |||
| 2024-03-31 | $40.00K 10-Q · filed 2025-05-08 | $40.00K derived: sum of 2 quarters · filed 2025-05-08 | $40.00K derived: sum of 3 quarters · filed 2025-05-08 | $40.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $0.00 derived: sum of 2 quarters · filed 2024-09-04 | $0.00 derived: sum of 3 quarters · filed 2024-09-04 | $345.00K 10-K/A · filed 2024-09-04 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $345.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $345.00K 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $345.00K 10-Q · filed 2023-05-25 | |||
| 2022-12-31 | $17.36K 10-K/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |